Found (56) clinical trials

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

This study is testing an oral investigational study drug in people who have been experiencing a decline in memory function, and/or who have been diagnosed with mild Alzheimer’s disease. The main objective of the study is to see whether this drug can slow the decline in memory and mental functioning ...

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...

Alzheimer’s disease (AD) is the most common cause of dementia. The deposition of extracellular amyloid plaques in the brain is a hallmark pathological finding in AD. These amyloid plaques are primarily composed of Aβ peptides. This study is to evaluate crenezumab, a monoclonal antibody, that has been shown to inhibit ...